Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Lymphoid 1Breast 1

Conditions

Carcinoma, Hepatocellular 81Colorectal Neoplasms 39Stomach Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Liver Neoplasms 14Neoplasms 11Melanoma 11Carcinoma, Renal Cell 11Esophageal Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Transitional Cell 8Breast Neoplasms 8Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Small Cell Lung Carcinoma 7Ovarian Neoplasms 7Head and Neck Neoplasms 7Cholangiocarcinoma 7Rectal Neoplasms 6Neoplasm Metastasis 6Colonic Neoplasms 6Urinary Bladder Neoplasms 5Gastrointestinal Neoplasms 5Carcinoma, Merkel Cell 5Biliary Tract Neoplasms 5Prostatic Neoplasms 4Sarcoma 3Lung Neoplasms 3Gallbladder Neoplasms 3

Interventions

pembrolizumab 7Nivolumab 3fludarabine 2durvalumab 2avelumab 2atezolizumab 2Cyclophosphamide 2tremelimumab 1fludarabine phosphate 1epacadostat 1bintrafusp alfa protein, human 1aldesleukin 1Therapeutics 1Temozolomide 1Surgical Procedures, Operative 1Specimen Handling 1Oxaliplatin 1Neoadjuvant Therapy 1Ipilimumab 1Interleukin-2 1Injections 1High-Throughput Nucleotide Sequencing 1Educational Status 1Drug Therapy 1Docetaxel 1Chemotherapy, Adjuvant 1Carboxylesterase 1Capecitabine 1Bevacizumab 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Microsatellite Instability × atezolizumab × Gastrointestinal × Clear all
NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

ImmunityBio, Inc.

Phase 2 Active not recruiting
40 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡